PMID- 34150414
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210622
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 13
IP  - 6
DP  - 2021 Jun 14
TI  - Atezolizumab, a PD-L1 Inhibitor: An Association of Bleeding Gastric Ulcer With 
      Its Use.
PG  - e15637
LID - 10.7759/cureus.15637 [doi]
LID - e15637
AB  - Atezolizumab is a programmed death-ligand 1 inhibitor, an immune checkpoint 
      inhibitor (ICI), useful in various advanced solid malignancies. As atezolizumab 
      is more commonly used nowadays, physicians should be aware of the rare associated 
      adverse events (AEs). Most of the AEs associated with the ICIs are 
      immune-related, and the common gastrointestinal (GI) manifestations are colitis 
      and diarrhea. Upper GI manifestations are rare with atezolizumab, and bleeding 
      gastric ulcer is even rarer. We report here a case of a 62-year-old male with 
      hepatocellular carcinoma who presented with upper GI bleed after atezolizumab 
      therapy. Esophagogastroduodenoscopy showed multiple gastric ulcers, which are 
      likely the cause of his bleeding.
CI  - Copyright (c) 2021, Bapatla et al.
FAU - Bapatla, Anusha
AU  - Bapatla A
AD  - Internal Medicine, Detroit Medical Center-Sinai Grace Hospital, Wayne State 
      University, Detroit, USA.
AD  - Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Tariq, Tooba
AU  - Tariq T
AD  - Gastroenterology and Hepatology, Wayne State University, Detroit, USA.
FAU - Haider, Maryam Bilal
AU  - Haider MB
AD  - Internal Medicine, Detroit Medical Center-Sinai Grace Hospital, Detroit, USA.
FAU - Mohamad, Bashar
AU  - Mohamad B
AD  - Gastroenterology and Hepatology, Wayne State University, Detroit, USA.
LA  - eng
PT  - Case Reports
DEP - 20210614
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC8208334
OTO - NOTNLM
OT  - atezolizumab
OT  - gastric ulcer
OT  - gastrointestinal manifestations
OT  - immune check point inhibitors
OT  - upper gastrointestinal manifestations
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/06/22 06:00
MHDA- 2021/06/22 06:01
PMCR- 2021/06/14
CRDT- 2021/06/21 05:57
PHST- 2021/06/21 05:57 [entrez]
PHST- 2021/06/22 06:00 [pubmed]
PHST- 2021/06/22 06:01 [medline]
PHST- 2021/06/14 00:00 [pmc-release]
AID - 10.7759/cureus.15637 [doi]
PST - epublish
SO  - Cureus. 2021 Jun 14;13(6):e15637. doi: 10.7759/cureus.15637.